Saturday, August 31, 2013

Organizing the Roleplay

I want this to be as interactive and as full of feedback from all the players as possible, so I'm creating this thread in the OOC to lay out MY goals for this roleplay and open the "forum" to everyone's input and suggestions so I can help YOU obtain YOUR goals in joining "Exploring Tarak".

I am here to flesh out all the details of my world, give some of my side characters from my novel some better development, and have fun putting some of my main characters in different scenarios. I intend the World of Tarak to be utilized for a good number of arcs and branch off into a number of groups delving into very different experiences - as this will help me further develop my geography, politics, history, etc for Tarak.

I am expecting the roleplay to pick up gradually and be maintained through the long term, with roleplayers having the opportunity to flow in and out as they please. Once a roleplayer has submitted their character and their starting location is available in the Places, they can feel free to begin posting. I'd like to get to know each of the characters that will be involved a bit through some character development posts and interaction with some "NPC"s from me, before determining a proper catalyst to bring them together. This should only take a few posts before I'm able to get a good enough idea for where to take it, and I will then enter appropriate Arcs and Quests into the roleplay.

As we get more roleplayers, I can see this expanding more into you all interacting with each other with a little less involvement on my end - as I will then be posting mainly the "events" that will help keep roleplay moving.

Those are my goals. Now...

What would each of you like to get out of this? What are your goals in joining this roleplay, and what suggestions do you have for me - things I can be doing / things you'd like to see that can help you obtain your goals?

May you rise up to meet the road before you, at times tortuous, volatile and grueling;
May you embrace the tempestuous elements that bear down upon you,
Until the sun shines warm upon your face.

Source: http://feedproxy.google.com/~r/RolePlayGateway/~3/bvwLmmkRN4Y/viewtopic.php

Ella Fitzgerald Kenny Vaccaro Kate McKinnon gwyneth paltrow Pink moon Schwab cispa

Former rebels sow terror in Central Africa Republic - residents


BANGUI | Fri Aug 30, 2013 8:22pm BST

BANGUI (Reuters) - Former rebels who seized power in Central Africa Republic are looting and killing indiscriminately in the country's remote northwest, residents said on Friday, amid mounting pressure for a firm international response to the crisis.

The mineral-rich but poor nation has descended into chaos since the Seleka rebels captured the capital Bangui in March, toppling President Francois Bozize and unleashing a wave of violence that new leader Michel Djotodia has failed to control.

French President Francoise Hollande called this week for urgent U.N. action to stabilise the nation of 4.5 million people at the heart of Africa, which has suffered a series of rebellions since independence from France in 1960.

The United Nations has said Central African Republic is on the brink of collapse. Aid organisations say there is a complete absence of state authority outside Bangui, with roaming armed groups looting and killing at will.

In the village of Ngaoundaye, about 500 km (300 miles) northwest of the capital, pastor Bernard Dilla said Seleka fighters chasing suspected bandits on Wednesday rounded up eight farmers in a field and shot them.

"They were furious at not catching the bandits so they turned on the farmers instead," Dilla told Reuters by telephone. "A young boy they had used as a tracker was also shot."

The pastor said Seleka gunmen also attacked the nearby village of Makele and torched 10 homes. In retaliation, the villagers killed two Seleka fighters with spears.

The day before, Seleka forces aboard four-by-four vehicles attacked the village of Bo, 50 km from Ngaoundaye, looting and burning homes and killing five people, residents said.

In Beboura, about 140 km east of Ngoundaye, villagers said Seleka gunmen killed a group of five young men on Friday after one of them argued with the fighters a day before.

Security Minister Josue Binoua declined to comment, saying a fact-finding mission would be dispatched on Saturday.

The incidents came after thousands of civilians fled to Bangui's international airport on Wednesday, blocking the tarmac for several hours, to escape marauding Seleka fighters. On Sunday, Seleka gunmen killed at least 13 people in an attack on the neighbourhood of Boy-Rabe in Bangui.

The African Union is deploying a 3,600-strong peacekeeping mission in Central African Republic, incorporating a regional force of 1,100 soldiers already on the ground.

France, which has a small force in Bangui securing the airport, wants the United Nations to provide financial and logistical support to the African Union mission, diplomats say.

Seleka, a grouping of five northern rebel movements, launched its insurgency in December, accusing Bozize of reneging on a 2007 peace deal.

(Writing by Bate Felix; Editing by Daniel Flynn and Alison Williams)

Source: http://uk.reuters.com/article/2013/08/30/uk-centralafrica-rebels-killings-idUKBRE97T0UL20130830?feedType=RSS&feedName=worldNews

elizabeth warren puerto rico diane sawyer Washington Election Results drudge report Presidential Election 2012 Incumbent

A look at Syria developments around the world

The United States is considering launching a punitive strike against the regime of Syrian President Bashar Assad, blamed by the U.S. and the Syrian opposition for an Aug. 21 chemical weapons attack in a rebel-held suburb of the Syrian capital of Damascus.

Here's a look at key Syria developments around the world Friday amid heightened tensions over potential military action:

UNITED STATES:

The U.S. government said it has "high confidence" that Syria's government carried out a chemical weapons attack ? killing 1,429 people, including at least 426 children. Those numbers are significantly higher than what Syrian activists and aid workers have reported from Syria. The U.S. chemical weapons assessment said Assad's government used an unidentified nerve agent, and cites human and satellite intelligence that it said backs up publicly available videos and other evidence.

SYRIA:

U.N. experts completed a final day of on-site visits in their investigation into the alleged use of chemical weapons in Syria. Shops and supermarkets in Damascus were filled with people stocking up on bread, canned food and candles ahead of expected strikes, but there were no apparent signs of panic or shortages. U.N. spokesman Martin Nesirky said the chemical weapons investigators visited a military hospital in Damascus in response to the Syrian government's allegations of three chemical weapons attack against Syrian soldiers earlier this month. The team is now packing and getting ready to leave Syria on Saturday.

UNITED NATIONS:

U.N. Secretary-General Ban Ki-moon privately briefed the five permanent members of the Security Council on the activities of the chemical weapons team. Nesirky said the team has concluded its collection of evidence related to the alleged Aug. 21 chemical weapons attack, including visits to field hospitals, interviews with witnesses and doctors, and gathering biological samples and environmental samples. He said U.N. disarmament chief Angela Kane will meet with Ban in New York on Saturday to give him a report on the investigation.

DENMARK:

NATO Secretary-General Anders Fogh Rasmussen from Copenhagen said the alliance has no plans for military action in Syria. He said approval for doing so would require the approval all 28 NATO members. But Rasmussen pointed the finger toward Syrian forces for the chemical weapons attack: "It demands cynicism beyond what is reasonable to believe that the opposition is behind a chemical attack in an area it already largely controls."

FRANCE:

French President Francois Hollande said his country can go ahead with plans to strike Syria for allegedly using chemical weapons despite the British parliament's failure to endorse military action. He told the newspaper Le Monde that the "chemical massacre of Damascus cannot and must not remain unpunished."

RUSSIA:

Presidential foreign policy adviser Yuri Ushakov expressed puzzlement over why the U.N. team had finished its work "when there are many questions about a possible use of chemical weapons in other areas in Syria." Russia has insisted there is no evidence the government is behind the attack. Russia and China have said that they would block any U.N. resolution that authorizes use of force against Syria's government.

BRITAIN:

Treasury chief George Osborne warned that Britain should not turn its back on the world after the stunning parliamentary defeat of a government motion for military intervention in Syria. He told the BBC there will be "national soul-searching" about Britain's global role after the "no" vote.

GERMANY:

German government spokesman Steffen Seibert said Germany isn't considering joining military action against Syria and hasn't been asked by others to do so. Berlin has called for the international community to take a "clear position" following the alleged chemical attack, but has left open what exactly that might entail.

IRAQ:

Followers of anti-American Shiite cleric Muqtada al-Sadr held rallies in Baghdad and the southern Iraqi city of Basra to denounce any Western strikes against Syria. In the capital, about 2,000 Sadrists demonstrated while chanting anti-American slogans after Friday prayers. About 3,000 Sadrists rallied in Basra, some carrying banners reading "No to America."

TUNISIA:

Foreign minister Othman Jerandi expressed opposition to any kind of foreign intervention in Syria, citing the "negative consequences" of any such operation. He called for "peaceful means and dialogue to find a solution to the crisis" to protect Syria's civilian population and preserve the country's territorial integrity.

Source: http://news.yahoo.com/look-syria-developments-around-world-152343775.html

mad hatter azerbaijan ryan howard ps i love you ray charles cheney heart transplant weather san diego

HSS uses grant to test new MRI techniques & biomarkers for arthritis prevention treatments

HSS uses grant to test new MRI techniques & biomarkers for arthritis prevention treatments [ Back to EurekAlert! ] Public release date: 30-Aug-2013
[ | E-mail | Share Share ]

Contact: Elyse Bernstein
bernsteinel@hss.edu
212-774-7258
Hospital for Special Surgery

$1 million Arthritis Foundation grant to help patients who develop arthritis after ACL tears, sports injuries

In recent years, researchers have been frustrated because there are no tools to identify early stages of osteoarthritis and thus no good way to test therapies for preventing or slowing the disease. Now, three institutions have been awarded $1 million from the Arthritis Foundation to validate the use of new MRI (magnetic resonance imaging) techniques and newly identified biomarkers to solve this vexing problem. Hospital for Special Surgery in New York City, University of California-San Francisco (UCSF), and Mayo Clinic in Rochester, Minnesota will share the $1 million.

"There is no magic bullet for treatment of osteoarthritis yet, but once we have a potential oral drug, therapeutic injection, or surgery for treating the disease, we will need a way to identify patients who might need it and follow their response to the treatment," said Scott Rodeo, M.D., orthopedic surgeon and co-chief of the sports medicine and shoulder service at Hospital for Special Surgery (HSS) and co-principal investigator of the tripartite grant. "Using X-rays to measure joint space narrowing is the gold standard for assessing the presence and progression of osteoarthritis, but X-rays are next to worthless for detecting the early changes of arthritis. This study will help us understand the early factors that lead to the degenerative changes in ACL (anterior cruciate ligament) injured knees."

Acute ACL injury is a major risk factor for developing osteoarthritis. In the past several years, researchers have discovered that long before osteoarthritic changes in joint space can be detected on X-ray, biochemical changes can be detected in cartilage using newer quantitative MRI techniques. Many studies have also shown that ACL injury is associated with quantifiable changes in biochemical biomarkers that can be detected in synovial fluid (joint fluid), blood, and urine.

The Arthritis Foundation grant will be distributed over one year and then the three grant recipients have made an institutional commitment to provide annual patient follow up after that. Each institution will recruit 25 patients who are at a maximum of 14 days out from tearing their ACL. Patients will be evaluated at baseline, six weeks, six months, 12 months and yearly thereafter with traditional MRI and newer MRI techniques.

Specifically, the new quantitative MRI techniques, developed by researchers at HSS and UCSF, measure T1? and T2 values of articular cartilage and the meniscus. Articular cartilage is the smooth cushion that lines the end of the bones where they meet at the joints. The meniscus is a knee structure that spans and cushions the space between the joint surfaces of the thighbone and shinbone. In scientific speak, T1? measures proteoglycan depletion, and T2 evaluates abnormal collagen orientation. Proteoglycans are conjugates of proteins and long carbohydrate molecules joined together with sugars.

"Imagine you are playing basketball and you jump up to make a basket, your ability to withstand the load when you come down is a function of proteoglycan," said Hollis Potter, M.D., chief of the division of magnetic resonance imaging, director of research in the Department of Radiology and Imaging at HSS. "If you pivot and throw the ball to someone else, your ability for your cartilage to withstand that load is a function of the collagen. You need both to be healthy." Dr. Potter is the HSS site leader of the grant.

At each time point that researchers collect MRI data, they will also collect samples of synovial fluid, blood, and urine from patients and evaluate knee function using surveys such as the Knee Outcome Survey, international knee documentation committee (IKDC) evaluation forms, and Marx Activity Level. These surveys gauge whether a patient has knee impairment; the degree of symptoms such as knee swelling and pain; and how much knee impairment impacts overall well-being, daily living, work, and athletic and social activities. The majority of participants in the study will undergo ACL reconstruction, and surgeons will evaluate these patients arthroscopically at the time of the operation. Clinicians will correlate fluid biomarkers and quantitative MRI results with traditional imaging, clinical, and functional outcomes.

Osteoarthritis is an extremely heterogeneous disorder in terms of the factors that contribute to the loss of joint function. Researchers need to be able to identify where a patient is in the progression of the disease to be able to target specific processes that are responsible for the symptoms and loss of joint function.

"Not everyone who has an ACL tear will develop osteoarthritis, but some do," said Dr. Rodeo. "The goal is to identify biomarkers that reflect alterations in the joint environment that may be predictive of developing arthritis." Once these are identified, researchers can test therapies to slow or prevent the disease, which can be crippling and lead to disability.

"There remain many unanswered questions regarding the optimal care of patients with ACL injuries," said Steven Goldring, M.D., Chief Scientific Officer, St. Giles Chair, Hospital for Special Surgery. "This study is a paradigm of interdisciplinary research that brings together experts in orthopedics, radiology and basic science from multiple leading medical centers with the single goal of developing the most effective therapies to improve outcomes in patients with ACL injuries. The Arthritis Foundation should be congratulated in initiating this groundbreaking program."

ACL ruptures affect roughly 1 in 3,000 people per year in the United States alone. The cumulative population risk of an ACL injury in people between the ages of 10 and 64 years has been estimated to be 5%, but could be considerably higher. More than 175,000 ACL reconstructions are performed each year in the United States at a cost of $2 billion. Participation in sports that involve pivoting including soccer, basketball, football, and skiing put individuals at higher risk for tearing their ACL.

###

About Hospital for Special Surgery

Founded in 1863, Hospital for Special Surgery (HSS) is a world leader in orthopedics, rheumatology and rehabilitation. HSS is nationally ranked No. 1 in orthopedics, No. 4 in rheumatology, and No. 5 in geriatrics by U.S. News & World Report (2013-14), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center three consecutive times. HSS has one of the lowest infection rates in the country. From 2007 to 2012, HSS has been a recipient of the HealthGrades Joint Replacement Excellence Award. HSS is a member of the New York-Presbyterian Healthcare System and an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at http://www.hss.edu.

Contacts

Elyse Bernstein
bernsteinel@hss.edu
212.606.1197

Tracy Hickenbottom
hickenbottomt@hss.edu
212.606.1197


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


HSS uses grant to test new MRI techniques & biomarkers for arthritis prevention treatments [ Back to EurekAlert! ] Public release date: 30-Aug-2013
[ | E-mail | Share Share ]

Contact: Elyse Bernstein
bernsteinel@hss.edu
212-774-7258
Hospital for Special Surgery

$1 million Arthritis Foundation grant to help patients who develop arthritis after ACL tears, sports injuries

In recent years, researchers have been frustrated because there are no tools to identify early stages of osteoarthritis and thus no good way to test therapies for preventing or slowing the disease. Now, three institutions have been awarded $1 million from the Arthritis Foundation to validate the use of new MRI (magnetic resonance imaging) techniques and newly identified biomarkers to solve this vexing problem. Hospital for Special Surgery in New York City, University of California-San Francisco (UCSF), and Mayo Clinic in Rochester, Minnesota will share the $1 million.

"There is no magic bullet for treatment of osteoarthritis yet, but once we have a potential oral drug, therapeutic injection, or surgery for treating the disease, we will need a way to identify patients who might need it and follow their response to the treatment," said Scott Rodeo, M.D., orthopedic surgeon and co-chief of the sports medicine and shoulder service at Hospital for Special Surgery (HSS) and co-principal investigator of the tripartite grant. "Using X-rays to measure joint space narrowing is the gold standard for assessing the presence and progression of osteoarthritis, but X-rays are next to worthless for detecting the early changes of arthritis. This study will help us understand the early factors that lead to the degenerative changes in ACL (anterior cruciate ligament) injured knees."

Acute ACL injury is a major risk factor for developing osteoarthritis. In the past several years, researchers have discovered that long before osteoarthritic changes in joint space can be detected on X-ray, biochemical changes can be detected in cartilage using newer quantitative MRI techniques. Many studies have also shown that ACL injury is associated with quantifiable changes in biochemical biomarkers that can be detected in synovial fluid (joint fluid), blood, and urine.

The Arthritis Foundation grant will be distributed over one year and then the three grant recipients have made an institutional commitment to provide annual patient follow up after that. Each institution will recruit 25 patients who are at a maximum of 14 days out from tearing their ACL. Patients will be evaluated at baseline, six weeks, six months, 12 months and yearly thereafter with traditional MRI and newer MRI techniques.

Specifically, the new quantitative MRI techniques, developed by researchers at HSS and UCSF, measure T1? and T2 values of articular cartilage and the meniscus. Articular cartilage is the smooth cushion that lines the end of the bones where they meet at the joints. The meniscus is a knee structure that spans and cushions the space between the joint surfaces of the thighbone and shinbone. In scientific speak, T1? measures proteoglycan depletion, and T2 evaluates abnormal collagen orientation. Proteoglycans are conjugates of proteins and long carbohydrate molecules joined together with sugars.

"Imagine you are playing basketball and you jump up to make a basket, your ability to withstand the load when you come down is a function of proteoglycan," said Hollis Potter, M.D., chief of the division of magnetic resonance imaging, director of research in the Department of Radiology and Imaging at HSS. "If you pivot and throw the ball to someone else, your ability for your cartilage to withstand that load is a function of the collagen. You need both to be healthy." Dr. Potter is the HSS site leader of the grant.

At each time point that researchers collect MRI data, they will also collect samples of synovial fluid, blood, and urine from patients and evaluate knee function using surveys such as the Knee Outcome Survey, international knee documentation committee (IKDC) evaluation forms, and Marx Activity Level. These surveys gauge whether a patient has knee impairment; the degree of symptoms such as knee swelling and pain; and how much knee impairment impacts overall well-being, daily living, work, and athletic and social activities. The majority of participants in the study will undergo ACL reconstruction, and surgeons will evaluate these patients arthroscopically at the time of the operation. Clinicians will correlate fluid biomarkers and quantitative MRI results with traditional imaging, clinical, and functional outcomes.

Osteoarthritis is an extremely heterogeneous disorder in terms of the factors that contribute to the loss of joint function. Researchers need to be able to identify where a patient is in the progression of the disease to be able to target specific processes that are responsible for the symptoms and loss of joint function.

"Not everyone who has an ACL tear will develop osteoarthritis, but some do," said Dr. Rodeo. "The goal is to identify biomarkers that reflect alterations in the joint environment that may be predictive of developing arthritis." Once these are identified, researchers can test therapies to slow or prevent the disease, which can be crippling and lead to disability.

"There remain many unanswered questions regarding the optimal care of patients with ACL injuries," said Steven Goldring, M.D., Chief Scientific Officer, St. Giles Chair, Hospital for Special Surgery. "This study is a paradigm of interdisciplinary research that brings together experts in orthopedics, radiology and basic science from multiple leading medical centers with the single goal of developing the most effective therapies to improve outcomes in patients with ACL injuries. The Arthritis Foundation should be congratulated in initiating this groundbreaking program."

ACL ruptures affect roughly 1 in 3,000 people per year in the United States alone. The cumulative population risk of an ACL injury in people between the ages of 10 and 64 years has been estimated to be 5%, but could be considerably higher. More than 175,000 ACL reconstructions are performed each year in the United States at a cost of $2 billion. Participation in sports that involve pivoting including soccer, basketball, football, and skiing put individuals at higher risk for tearing their ACL.

###

About Hospital for Special Surgery

Founded in 1863, Hospital for Special Surgery (HSS) is a world leader in orthopedics, rheumatology and rehabilitation. HSS is nationally ranked No. 1 in orthopedics, No. 4 in rheumatology, and No. 5 in geriatrics by U.S. News & World Report (2013-14), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center three consecutive times. HSS has one of the lowest infection rates in the country. From 2007 to 2012, HSS has been a recipient of the HealthGrades Joint Replacement Excellence Award. HSS is a member of the New York-Presbyterian Healthcare System and an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at http://www.hss.edu.

Contacts

Elyse Bernstein
bernsteinel@hss.edu
212.606.1197

Tracy Hickenbottom
hickenbottomt@hss.edu
212.606.1197


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2013-08/hfss-hug082913.php

Friends Reunion Elena Delle Donne usa today yahoo news Google News Pray For Boston Anne Frank

J&J launches new cap to curb Tylenol overdoses

This undated product image provided by Johnson & Johnson shows a bottle of Extra Strength Tylenol bearing a new warning label on the cap alerting users to potentially fatal risks of taking too much of the pain reliever. Johnson & Johnson, the company that makes Tylenol, says the warning will appear on the cap of each new bottle of Extra Strength Tylenol sold in the U.S. in October 2013 and on all other Tylenol bottles in coming months. (AP Photo/Johnson & Johnson)

This undated product image provided by Johnson & Johnson shows a bottle of Extra Strength Tylenol bearing a new warning label on the cap alerting users to potentially fatal risks of taking too much of the pain reliever. Johnson & Johnson, the company that makes Tylenol, says the warning will appear on the cap of each new bottle of Extra Strength Tylenol sold in the U.S. in October 2013 and on all other Tylenol bottles in coming months. (AP Photo/Johnson & Johnson)

(AP) ? Bottles of Tylenol sold in the U.S. will soon bear red warnings alerting users to the potentially fatal risks of taking too much of the popular pain reliever. The unusual step, disclosed by the company that makes Tylenol, comes amid a growing number of lawsuits and pressure from the federal government that could have widespread ramifications for a medicine taken by millions of people every day.

Johnson & Johnson says the warning will appear on the cap of new bottles of Extra Strength Tylenol sold in the U.S. starting in October and on most other Tylenol bottles in coming months. The warning will make it explicitly clear that the over-the-counter drug contains acetaminophen, a pain-relieving ingredient that is the nation's leading cause of sudden liver failure.

"We're always looking for ways to better communicate information to patients and consumers," says Dr. Edwin Kuffner, vice president of McNeil Consumer Healthcare, the Johnson & Johnson unit that makes Tylenol.

Overdoses from acetaminophen send 55,000 to 80,000 people in the U.S. to the emergency room each year and kill at least 500, according to the Centers for Disease Control and Prevention and the Food and Drug Administration. Acetaminophen can be found in more than 600 over-the-counter and prescription products used by nearly one in four American adults every week, including household brands like Nyquil cold formula, Excedrin pain tablets and Sudafed sinus pills.

Tylenol is the first of these products to include such a warning label on the bottle cap. McNeil says the warning is a result of research into the misuse of Tylenol by consumers. The new cap message will read: "CONTAINS ACETAMINOPHEN" and "ALWAYS READ THE LABEL."

The move comes at a critical time for the company, which faces more than 85 personal injury lawsuits in federal court that blame Tylenol for liver injuries and deaths. At the same time, the Food and Drug Administration is drafting long-awaited safety proposals that could curtail the use of Tylenol and other acetaminophen products.

Much is at stake for McNeil and its parent company. Johnson & Johnson does not report sales of Tylenol, but total sales of all over-the-counter medicines containing acetaminophen were more than $1.75 billion last year, according to Information Resources Inc., a retail data service.

Safety experts are most concerned about "extra-strength" versions of Tylenol and other pain relievers with acetaminophen found in drugstores. A typical two-pill dose of Extra Strength Tylenol contains 1,000 milligrams of acetaminophen, compared with 650 milligrams for regular strength. Extra Strength Tylenol is so popular that some pharmacies don't even stock regular strength.

Most experts agree that acetaminophen is safe when used as directed, which generally means taking 4,000 milligrams, or eight pills of Extra Strength Tylenol or less, a day.

Each year, some 100 million Americans use acetaminophen, but liver damage occurs in only a fraction of 1 percent of users. Still, liver specialists say those cases are preventable. Part of the problem, they say, is that there are sometimes hundreds of pills in a bottle, making it easy for consumers to pop as many as they please. For example, McNeil sells Extra Strength Tylenol in bottles containing up to 325 tablets

"The argument goes that if you take acetaminophen correctly you will virtually never get into trouble," says Dr. William Lee of the UT Southwestern Medical Center, who has studied acetaminophen toxicity for four decades. "But it's the very fact that it's easily accessible over-the-counter in bottles of 300 pills or more that puts people in harm's way."

Lee applauded the new warning, but said McNeil's marketing has contributed to the "freewheeling" way that Americans take the drug. For decades, McNeil has advertised Tylenol as "the safest kind of pain reliever" when used as directed. "That has been their standard ploy in the past, and I would argue that safest it is not," he says.

McNeil's Kuffner stands by the company's safety claim: "When taken as directed, when people read and follow the label, I believe that Tylenol and the acetaminophen ingredient is one of the safest pain relievers on the market."

McNeil is the only major drugmaker adopting the bottle cap warning at this time, according to the Consumer Healthcare Products Association, a trade group for over-the-counter medicine companies.

"While this is not an industrywide initiative at this time, it fits squarely within the many ongoing industrywide educational initiatives to further acetaminophen safe and responsible use by consumers," said Emily Skor, a vice president with the trade group, which represents McNeil, Bayer Healthcare, Procter & Gamble and other nonprescription drugmakers.

20 YEARS OF WARNINGS

McNeil has updated the safety warnings on Tylenol periodically since the 1990s.

In 1994, the company added a warning about the risk of liver damage when combining alcohol with Tylenol following a lawsuit brought by Antonio Benedi, a former aide to President George H.W. Bush, who fell into a coma and underwent emergency liver transplant after mixing Tylenol with wine at dinner.

A jury awarded him $8.8 million in damages after concluding that McNeil failed to warn consumers about the risk. The FDA made the alcohol warning mandatory for all manufacturers of acetaminophen in 1998.

Then, in 2002, an expert panel of FDA advisers recommended that the government agency require all acetaminophen products to carry a warning about the risk of "severe liver damage" when not taken as directed. The group's votes are non-binding, though the FDA usually follows them. McNeil voluntarily added the warning to its products in 2004, five years before the FDA made it mandatory.

Today, McNeil appears to be moving ahead of regulators again. In 2009, the FDA assembled another expert panel to consider more sweeping changes to reduce acetaminophen overdoses. The panel recommended a half-dozen major changes, including lowering the maximum nonprescription daily dose for adults. McNeil voluntarily adopted that recommendation, lowering the recommended adult dose of Extra Strength Tylenol to 3,000 milligrams per day, or six pills of Extra Strength Tylenol, down from 4,000 milligrams per day, or eight pills. The label stipulates that patients can still take a higher dose under doctor's directions.

But the company has not embraced a more drastic recommendation by the FDA's expert panel: eliminating the over-the-counter "extra-strength" formulation altogether, which would mean lowering the acetaminophen dose from 1,000 milligrams to 650 milligrams, or two tablets of 325 milligrams each. The panel said the 1,000 milligram dose should only be available via prescription.

McNeil argues that the lower dose is less effective and could drive people to take anti-inflammatory pain relievers, a different class of drugs that includes aspirin and ibuprofen. Those medicines can cause stomach ulcers and dangerous gastrointestinal bleeding.

FDA spokeswoman Erica Jefferson says the agency is actively working on new rules for both children and adult acetaminophen products. While the agency won't give a timeframe for completion, the federal government's website that tracks new regulations lists December as the target date for publishing the proposed rules.

As early as 1977, FDA advisers recommended adding more warnings to the acetaminophen label about liver damage, but the agency didn't require the language until 2009.

"They are very slow to respond to these things and it's always a little frustrating," says Dr. Lewis Nelson of New York University, who chaired the 2009 FDA panel.

ANATOMY OF AN OVERDOSE

Experts first identified acetaminophen overdose as a major public health concern in the 1990s, but it has taken years to form a clearer picture of the problem.

Acetaminophen overdoses occur when the liver is overwhelmed by too much of the drug, producing a toxic byproduct that kills liver cells. Liver failure occurs when most cells are no longer able to function. At that point, a patient then generally has 24 to 48 hours to live without a transplant.

Of the roughly 500 acetaminophen deaths reported annually, about half are accidental, with the rest deemed suicides. About 60 percent of the unintentional overdoses involve prescription opioid-acetaminophen combination drugs such as Percocet and Vicodin, according to a database of liver failure cases run by Dr. Lee at the Southwestern Medical Center in Dallas. Those two products alone were prescribed more than 173 million times last year, according to IMS Health.

So how do these accidental acetaminophen deaths occur? Imagine you've had major dental surgery, and your dentist prescribes a five-day supply of Percocet. You take the recommended two pills every six hours for 2,600 milligrams of acetaminophen, well below the 4,000-milligram-a-day safety threshold.

But you're still experiencing pain, so you decide to add Extra Strength Tylenol, six caplets a day for another 3,000 milligrams. Now you're feeling better but you still have trouble sleeping, so you take Nyquil, for another 650 milligrams. After a few days on this 6,250 milligram regimen, experts say acute liver damage is a real risk.

The labels on all of these products warn against mixing them. But researchers say many consumers either don't read or don't understand such warnings.

Even after taking into account people who ignore labels, there are still cases of liver damage that stump researchers. These are the people who have apparently taken about 4,000 milligrams a day or less, well within the safety threshold.

"It's still a little bit of a puzzle," says Dr. Anne Larson, of the Swedish Medical Center in Seattle. "Is it genetic predisposition? Are they claiming they took the right amount, but they really took more? It's difficult to know."

The question is critical in the lawsuits piling up against McNeil in the Eastern District of Pennsylvania, near McNeil's headquarters in Fort Washington, Pa. Virtually all of the 85 cases claim that the plaintiffs suffered liver failure despite taking Tylenol as directed.

According to one of those complaints, Madeline Speal, of Salzburg, Pa., took Tylenol for three days in November 2009 "at appropriate times and in appropriate doses." But on Nov. 28, she was admitted to Latrobe Area Hospital with catastrophic liver damage. She was then transferred to the University of Pittsburgh Medical Center where she underwent an emergency liver transplant.

The cases against McNeil, which share the same legal wording, allege that the company risked the lives of consumers by making "conscious decisions not to redesign, re-label, warn or inform the unsuspecting consuming public."

The lawsuits have been consolidated under a single federal judge to streamline the pretrial process, though they will eventually be returned to judges in their original districts for trial.

J&J and McNeil continue to reiterate that Tylenol is safe. "We remain confident in the safety and efficacy of Tylenol products, which rightfully have been trusted by doctors, hospitals and consumers for more than 50 years," McNeil said in a statement.

But lawyers for the patients suing McNeil say Tylenol can still be dangerous even when used at or just above recommended levels.

"Products that are available to consumers should have a reasonable margin of safety," said Laurence Berman, one of several attorneys representing Tylenol users.

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/386c25518f464186bf7a2ac026580ce7/Article_2013-08-29-Tylenol-Warning%20Label/id-8570a6cf24804c4c8a1dc7267a3759d3

modesto st louis weather guinea bissau google stock google stock china gdp dont trust the b in apartment 23

Friday, August 30, 2013

app : Skype voor je iPad downloaden

Zeg "hallo" tegen vrienden en familie via een chatbericht of een spraak- of videogesprek ? gratis, via Skype. Er is zo veel dat u gewoon vanuit de palm van uw hand kunt doen.

Functies:
Sluit u aan bij de meer dan 250 miljoen mensen die elke maand Skype gebruiken
- Profiteer van Skype op uw iPad en vind uw vrienden in een oogwenk.

Bel vrienden op Skype
- Geniet van gratis bellen en videobellen met iedereen die ook op Skype zit en voer videogesprekken in HD-kwaliteit vanaf uw iPad 4.

Verstuur chatberichten
- Stuur uw vrienden chatberichten en voeg er emoticons aan toe.

Videoberichten versturen
- Houd contact met vrienden en familie, zelfs als ze bezet of offline zijn, via onbeperkte gratis videoberichten.

Foto's delen
- Verstuur foto's vanaf uw iPad via Skype rechtstreeks naar vrienden of familie. Het maakt niet uit hoe groot het fotobestand is, dus maak u geen zorgen over het overschrijden van e-maillimieten of hoge mms-kosten.

Bel vaste en mobiele nummers
- Koop wat Skypetegoed om vrienden voordelig te sms'en of te bellen op hun vaste of mobiele nummer.

Geen wifi? Geen probleem
- Skype doet het via 3G* net zo goed als via wifi, dus u kunt altijd contact houden, waar u ook bent.

Spreek met wie u wilt, waar u maar wilt
- Skype is er voor smartphones, tablets, pc's, Mac's en zelfs tv's. Wat uw vrienden of familie ook gebruiken, Skype werkt gewoon. Simpel.

Zoek in de App Store naar andere geweldige apps van Skype:
- Skype voor iPhone
- Skype WiFi
- GroupMe

* Provider kan kosten in rekening brengen

Systeemvereisten:
- iOS 5 of hoger.
- Verstuur tijdens een videogesprek beelden met behulp van de camera voor of achter op uw iPad 2, 3e en 4e generatie iPad of iPad mini.
- Werkt met alle H.264-compatibele apparaten, inclusief tv's.

Verbeteringen in de gesprekskwaliteit
- Voer videogesprekken in HD-kwaliteit vanaf uw iPad 4.
- Algemene verbeteringen in de gesprekskwaliteit en de stabiliteit.

Algemene oplossingen en verbeteringen
- Vernieuwde landnummerkiezer op het nummertoetsenblok.

Source: http://www.bookmarksurfer.com/showcoll.php?id=52202caf0f38d

stacey dash christopher columbus columbus day columbus day Stacy Dash Amber Tamblyn Lilit Avagyan

Rumor: T-Mobile Blacks Out Employee Vacation for Sep. 20th iPhone Launch

If history is anything to go by, we?ll see Apple?s latest iPhone launch on Friday, September 20th. We?ve heard for a while that Apple plans to announce the iPhone 5S and possible iPhone 5C on September 10th at an event in San Francisco. Looking at every previous year since the iPhone 3G, the actual public release always happens a week and a half later, the following Friday.

This year, September 10th falls on a Tuesday, and the following Friday is September 20th. New rumors from TmoNews indicate T-Mobile has blacked out employee vacation days starting starting that day, throughout the weekend. As we?ve seen happen before with other carriers, launch day and launch weekend sales are through the roof, as iPhone users waiting for an upgrade are camped out the night before. In fact, most Apple stores and carrier stores are all but sold out after just the first day.

As of right now, although none of this has officially been confirmed by Apple, I?d wager serious money on a September 10th announcement date and a September 20th release date for the iPhone 5S and possibly the iPhone 5C. I also wouldn?t hold my breath on seeing new iPads at this event. Instead, I?d bet those will come in October, with plenty of time to get them on the shelves before the holiday shopping season. As always, I?ll keep you posted.

??

You should follow?Mike on Twitter for more great tech insights and good conversation. Be sure to say hello! You can also keep up with Mike on his personal blog:?MikeBeauchamp.me, on?Facebook, or on?Google+.

Source: http://www.zagg.com/community/blog/iphone-5s-launch-september-20/

riley reiff david decastro travis pastrana aj jenkins shea mcclellin nfl draft 2012 whitney mercilus